



A Quick Look at Using Meningococcal Conjugate Vaccines For Persons Aged 11 Years and Older

Age Indications for MenACWY Vaccines (MCV4)

Menveo® (MenACWY-CRM): for ages 2 months through 55 years

Menactra® (MenACWY-D): for ages 9 months through 55 years

Indications for Use and Schedule

• Routinely administer:

- One dose at aged 11-12 years¹; 2nd dose at age 16 years
- Preferred for ages 56 years & older who previously received MenACWY or who are recommended to receive multiple doses of meningococcal vaccine*

• Adolescent catch-up schedule:

- If 1st dose given at aged 13 through 15 years, give a 2nd dose at aged 16 through 18 years²
- If 1st dose given at age 16 years or older, a 2nd dose is not recommended

• Minimum interval

- 8 weeks between 2 doses

Vaccine Administration

- Intramuscular (IM) injection in the deltoid of the arm
 - 1-1.5 inch, 22-25 gauge needle
- Use professional judgment in selecting needle length
- Give simultaneously with all vaccines with this exception:
 - If using Menactra for asplenic persons, ensure PCV13³ is given first and then Menactra at least 4 weeks later⁴

Storage and Handling

- Store in the refrigerator between 35°-46° F (2°-8° C)
 - Stand-alone storage units are preferred
- Do not freeze vaccine; Keep in the original box
- Menactra is ready to use; shake well
- Menveo must be reconstituted
 - Draw up MenCYW liquid (diluent)
 - Add to Men A vial; invert and shake well
- Administer vaccines immediately after drawn up in syringe

*PERSONS WITH CERTAIN MEDICAL OR OTHER RISK CONDITIONS

- Persons aged 11 years & older with persistent terminal complement deficiency or asplenia (functional or anatomic):
 - 2-dose primary series (0, 2 months) & a booster dose every 5 years thereafter
- Persons aged 11 years & older who are at increased risk due to prolonged exposure (e.g., travel to/living in endemic areas, current outbreak, microbiologists exposed to *N. meningitidis*) or when required (e.g., military recruits, travel to Mecca during annual Hajj):
 - Give 1 dose; if the person remains at increased risk, a booster dose is recommended 5 years later
- Persons with HIV and an indication for vaccination should receive a 2-dose primary series (0, 2 months)
 - Need and interval for booster dose determined by risk factor
 - HIV without another risk factor present is not a medical indication for meningococcal vaccination
- Ensure students age 21 years or younger who are entering college/living in dorm have received a dose in the last 5 years
 - Consider 1 dose of MenACWY for students age 21 years or younger & currently attending college, with no dose in the last 5 years
 - MenACWY is not routinely recommended for healthy persons age 22 years or older

CONTRAINDICATIONS

- An anaphylactic (severe allergic) reaction to a prior dose or a component of MenACWY vaccine

PRECAUTIONS

- Moderate to severe acute illness with or without a fever

FURTHER POINTS

- Persons indicated for a 2-dose primary series who previously received only 1 dose of MenACWY, should get a 2nd dose of MenACWY as soon as feasible; forecast for the booster dose (if applicable) from the date of the 2nd primary series dose
- Persons aged 56 years or older who have never received a meningococcal vaccine and anticipate needing only one dose, MPSV4 (meningococcal polysaccharide vaccine) is preferred
- Persons who inadvertently receive MPSV4 should be revaccinated with MenACWY using a minimum interval of 8 weeks
- Meningococcal B (MenB) vaccines are discussed in a separate Quick Look posted at www.michigan.gov/immunize
- MenACWY Vaccine Information Statement (VIS), including information about the Michigan Care Improvement Registry (MCIR), can be found at www.michigan.gov/immunize or your local health department
- Document Menactra as "MCV4 (Menactra)" and Menveo as "MCV4 (Menveo)" in MCIR
- Document as MenACWY (Menactra) or MenACWY (Menveo) on immunization record card and/or chart or EMR
- Use the lot number on the outside box of Menveo to document in MCIR and on the vaccine record

¹ If MenACWY is given at age 10 years, will count as the age 11-12 years/1st dose of the adolescent series; give next dose at age 16 years

² Recommended interval is 3-5 years but if unlikely to return at later date, give 2nd dose at age 16 years and at least 8 weeks after last dose

³ PCV13 = Pneumococcal Conjugate Vaccine; ensure at least one dose of PCV13 (Prenvar13[®]) is given to all persons with asplenia

⁴ For persons aged 2 years or older with asplenia, give the PCV13 dose 1st and wait 4 weeks before giving Menactra (MenACWY-D). Menveo (MenACWY-CRM) can be given at the same time or at any interval before/after PCV13.

Publicly purchased MenACWY can be administered to eligible children aged 2 months through 18 years with an indication for vaccination through the Vaccines for Children (VFC) Program in private providers' offices. Eligible children include those who are uninsured, underinsured, Medicaid eligible, Native American or Alaskan Natives. Contact your local health department for more information. Resource: "Prevention and Control of Meningococcal Disease, Recommendations of the ACIP", March 22, 2013, located at www.cdc.gov/vaccines/recs. Updates to this Quick Look handout will be posted at www.michigan.gov/immunize under "Health Care Professionals/Providers."